The NHS in England will offer weight-loss drugs to more than one million people who are overweight or obese and at risk of serious cardiovascular events. According to The Guardian, the National Institute for Health and Care Excellence (NICE) has recommended semaglutide, sold under brand names Wegovy and Ozempic, for individuals with a body mass index (BMI) score of 27 or above who have had heart attacks, strokes, or serious circulation problems.
Key Takeaways
The NHS in England will offer weight-loss drugs like semaglutide (Wegovy) to over one million people who are overweight or obese and at risk of heart attacks and strokes. This decision follows a recommendation by NICE, highlighting clinical trials showing reduced cardiovascular risks.
- The NHS will provide semaglutide injections to 1.2 million eligible individuals
- Clinical trials show the drug reduces major cardiac events by 20%
- Patients with BMI 27+ and history of heart issues qualify for treatment
- Treatment includes diet, exercise, and existing medications like statins
Clinical trials cited by The Guardian, BBC, and Sky News show that semaglutide reduces the risk of major cardiovascular events by 20%. The drug works on the heart and blood vessels directly, not just through weight loss. Helen Knight from NICE stated that this treatment offers an 'extra layer of protection' for those already taking other heart medicines.
The NHS plans to roll out semaglutide treatments within months. According to Sky News, the drug will be available as a weekly injection, self-administered at home using a special pen injector device. Patients will also receive guidance on diet and exercise alongside their existing medications like statins.
The decision has been welcomed by health experts, including Dr Sonya Babu-Narayan from the British Heart Foundation, who highlighted the drug's benefits beyond weight loss. However, some experts have raised concerns about potential side effects such as bloating, nausea, and reduced muscle mass if physical activity is not maintained.
How this summary was created
This summary synthesizes reporting from 3 independent publishers using AI. All sources are cited and linked below. NewsBalance is a news aggregator and media literacy tool, not a news publisher. AI-generated content may contain errors or inaccuracies — always verify important information with the original sources.